Chronic nerve pain may have a hidden switch in the brain, and flipping it back could provide a new treatment method without relying on widespread opioid use.
The brain’s pain control fails after injury
A small region in the brainstem, the locus coeruleus (LC), usually helps reduce pain by releasing norepinephrine. After nerve damage, this area can reverse its function, increasing pain signals instead of suppressing them. Recent research in mice indicates that restoring a specific opioid signaling system in the LC may reverse this change, offering a potential target for neuropathic pain treatment.
The findings, published in Current Biology, show that nerve injury weakens a natural opioid-mediated mechanism in the LC. When this mechanism fails, the region contributes to ongoing pain. Scientists at Washington University School of Medicine used optogenetics to temporarily inhibit LC activity in mice with long-term nerve injuries. Four weeks after injury, silencing these neurons decreased pain sensitivity, particularly in pathways linking the LC to the medial prefrontal cortex, an area involved in pain and emotion.
Related: Chilled Platelets Could Expand Patient Supply
Opioid receptors function like a circuit breaker
Researchers then examined mu opioid receptors (MORs) on LC neurons. These receptors respond to the body’s natural opioids and typically reduce LC activity. After nerve injury, their function varies depending on the neural pathway they regulate.
Removing MORs from LC neurons connected to the medial prefrontal cortex increased pain sensitivity. However, removing the same receptors from neurons linked to the spinal cord had the opposite effect, reducing pain. This demonstrates that the opioid system in the LC does not act as a simple switch—its role in pain depends on the specific circuit.
Restoring MOR signaling in the LC reversed pain hypersensitivity in mice. The results suggest that the body’s natural opioids remain available after injury and can still activate reinstated receptors, offering a possible treatment approach.
The brain’s adaptability is usually beneficial, but in chronic pain, this flexibility can work against recovery. The LC’s shift from pain suppressor to pain amplifier may explain why some patients develop lasting hypersensitivity after nerve damage. If humans share this mechanism, treatments could focus on restoring localized opioid signaling rather than using broad-acting opioids.
Related: Genetic Screening Could Reveal Early Cancer Risk in Newborns
The study’s authors stated that their work “adds critical new evidence that loss of LC-MOR may drive the shift from an acute pain-relief system to a chronic pain generator.” While still in early stages, the research suggests therapies could selectively restore opioid function in the LC without the risks of systemic opioid use.
One obstacle will be understanding how LC opioid signaling changes over time in chronic pain patients. The mouse model used a spared nerve injury, which may not fully reflect human conditions. Nevertheless, the results indicate that the body’s opioid system could be used more precisely than previously believed.
Restoring MOR function in the LC may become a therapeutic target for chronic pain, the authors concluded.
Leave a Reply